Inhibition of HIV-1 infection by high active antiretroviral therapy (HAART) has profoundly improved the morbidity and mortality of HIV-1infected patients. However, the transmission of multidrug-resistant HIV strains is becoming a growing problem in newly-infected persons as the efficacy of HAART is compromised and therapeutic options are consequently limited. In the January 3 issue of the Journal of Clinical investigation, Joachim Hauber and colleagues from The Heinrich-Pette-Institute for Experimental Virology and Immunology in Hamburg report that inhibition of cellular deoxyhypusine synthase with the molecule CNI-1493 was able to suppress the replication of HIV-1 strains highly resistant to other drugs, with no measurable drug-induced effects on cell growth. Human deoxyhypusine synthase represents a novel and promising drug target for development of advanced antiretroviral therapies, particularly for the inhibition of multidrug-resistant viruses.
TITLE: Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy
AUTHOR CONTACT:
Joachim Hauber
Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany.
Phone: 49-40-480-51-241; Fax:49-40-480-51-184; E-mail: joachim.hauber@hpi.uni-hamburg.de.
View the PDF of this article at: https://www.the-jci.org/press/21949.pdf http://www.jci.org/cgi/content/full/115/1/76.
SDF-1 is necessary and sufficient to promote eye disease that results in blindness
Proliferative retinopathy, characterized by the abnormal formation of blood vessels in the retina, is a major cause of blindness in working-age adults. In humans, levels of stromal cellderived factor 1 (
'"/>
Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Jan-2005